Credibility Advisory Board

John Huxter is Associate Director and Cognition Lead at Transpharmation, and is CAB's industry representative. John has had more than 25 years of neuroscience experience in both academia and industry, and across diverse therapeutic areas including psychiatric disorders, chronic pain, and neurodegeneration. With a background in both behaviour and electrophysiology (UCL, University of Bristol, Oxford’s MRC Analytical Neuropharmacology Unit), he has led biomarker discovery and assay development efforts at both Pfizer and Eli Lilly before joining Transpharmation in 2020. John is passionate about the translational potential for preclinical neuroscience, and works closely with the Transpharmation teams in the UK, Ireland, Poland and Canada to explore new opportunities for drug discovery and collaboration. 

Emily Sena is a Stroke Association Kirby Laing Foundation Senior Non-Clinical Lecturer at the University of Edinburgh. She is specialised in the validity of preclinical research. Her interests are in the use of meta-research approaches (research on research) to drive improvements in the validity, transparency and reproducibility of primary research using animal models of human diseases. Her work has informed laboratory practice guidelines, editorial policy and clinical trials design. Emily is the inaugural Editor-in-Chief of BMJ Open Science, and convenor of CAMARADES.